p53 inhibits CRISPR-Cas9 engineering in human pluripotent stem cells.

Autor: Ihry RJ; Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Worringer KA; Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Salick MR; Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Frias E; Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Ho D; Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Theriault K; Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Kommineni S; Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Chen J; Department of Oncology, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Sondey M; Abbvie, Cambridge, MA, USA., Ye C; Blueprint Medicine, Cambridge, MA, USA., Randhawa R; Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Kulkarni T; Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Yang Z; Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., McAllister G; Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Russ C; Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Reece-Hoyes J; Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Forrester W; Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Hoffman GR; Department of Chemical Biology and Therapeutics, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Dolmetsch R; Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA., Kaykas A; Department of Neuroscience, Novartis Institutes for Biomedical Research, Cambridge, MA, USA. ajamete.kaykas@novartis.com.
Jazyk: angličtina
Zdroj: Nature medicine [Nat Med] 2018 Jul; Vol. 24 (7), pp. 939-946. Date of Electronic Publication: 2018 Jun 11.
DOI: 10.1038/s41591-018-0050-6
Abstrakt: CRISPR/Cas9 has revolutionized our ability to engineer genomes and conduct genome-wide screens in human cells 1-3 . Whereas some cell types are amenable to genome engineering, genomes of human pluripotent stem cells (hPSCs) have been difficult to engineer, with reduced efficiencies relative to tumour cell lines or mouse embryonic stem cells 3-13 . Here, using hPSC lines with stable integration of Cas9 or transient delivery of Cas9-ribonucleoproteins (RNPs), we achieved an average insertion or deletion (indel) efficiency greater than 80%. This high efficiency of indel generation revealed that double-strand breaks (DSBs) induced by Cas9 are toxic and kill most hPSCs. In previous studies, the toxicity of Cas9 in hPSCs was less apparent because of low transfection efficiency and subsequently low DSB induction 3 . The toxic response to DSBs was P53/TP53-dependent, such that the efficiency of precise genome engineering in hPSCs with a wild-type P53 gene was severely reduced. Our results indicate that Cas9 toxicity creates an obstacle to the high-throughput use of CRISPR/Cas9 for genome engineering and screening in hPSCs. Moreover, as hPSCs can acquire P53 mutations 14 , cell replacement therapies using CRISPR/Cas9-enginereed hPSCs should proceed with caution, and such engineered hPSCs should be monitored for P53 function.
Databáze: MEDLINE
Externí odkaz: